Biosyent (RX) Q1 2025 earnings summary

Executive summary

• Achieved record Q1 2025 sales of $10.98 million, up 42% year-over-year, with EBITDA rising 45% to $3.20 million and a 29% margin.

• Net income after tax was $2.32 million, representing a 21% margin and a 31% year-over-year increase.

• 59 consecutive profitable quarters since Q2 2010.

• FeraMAX® Pd and Tibella® sales grew 18% and 53% year-over-year, respectively, maintaining leadership in the Canadian iron health market.

• First international shipments of Tibelia® generated $0.8 million in new revenue.

Financial highlights

• Q1 2025 diluted EPS reached $0.20, up from $0.15 in Q1 2024; trailing 12-month EPS rose to CAD 0.67.

• Cash and investments at March 31, 2025, ranged from $17.4 million to $27.8 million, with no debt.

• Trailing twelve months cash from operations totaled $7.0 million.

• Return on equity for TTM was 22%, up from 15% a year ago.

• Returned $6.2 million to shareholders via buybacks and dividends in the last 12 months.

Outlook and guidance

• Revenue and profit growth expected to continue in 2025, with a solid start to the year and further international deliveries of Tibelia® planned.

• Order book and production scheduling filled for the remainder of 2025 and into Q1 2026.

• Additional FeraMAX® product development underway, targeting a 2026 launch.

• Focus remains on long-term, profitable growth and portfolio diversification.